Market Overview:
The global thalomid market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of multiple myeloma, increasing demand for thalomid in emerging markets, and growing focus on research and development (R&D) activities for new drug therapies. Based on type, the global thalomid market is segmented into 50mg, 100mg, and 200mg. The 100mg segment is expected to account for the largest share of the global thalomid market in 2018. This can be attributed to its higher efficacy as compared with other dosages and its growing use in combination with other drugs for treating multiple myeloma. Based on application, the global thalomid market is segmented into retail pharmacy, hospital pharmacy, and other applications. The retail pharmacy segment accounted for the largest share of the global thalomid market in 2017 owing to rising demand from patients diagnosed with multiple myeloma across developed countries such as U.S.
Product Definition:
Thalomid is a trade name for the drug lenalidomide, which is used to treat multiple myeloma and mantle cell lymphoma.
50mg:
50mg is used for the treatment of chronic insomnia. It is also used to treat conditions associated with the immune system, such as multiple sclerosis and lupus. The drug has a low risk of causing drowsiness; however, it may cause sleep disturbance if taken late in the day. 50mg tablets are usually prescribed for people who have been unable to sleep for more than two nights in a row on at least two occasions per month.
100mg:
Thalomid is used for the treatment of multiple myeloma, essential thrombocytopenia, and chronic idiopathic polyneuropathy. It works by increasing the levels of granulocyte colony-stimulating factor in your blood.
100mg Thalomid contains: Prednisolone acetate as it's base and prednisolone palmitate (as an additional component).
Application Insights:
The other application segment includes the use of thalomid for Horses and Other Animals. The retail pharmacy was the dominant segment accounting for over 60% of the overall revenue in 2017. It is expected to continue its dominance over the forecast period owing to increasing awareness about generic drugs and growing preference towards cheaper medicines in developing countries like India, China, Brazil etc. Retail pharmacies are generally located near hospitals or medical stores as these stores have a high volume of customers requiring parenteral nutrition (PN) solutions such as thalomid.
Hospital pharmacies are anticipated to witness significant growth with CAGR 5% from 2018 to 2030 on account of various factors such as government initiatives encouraging adoption in hospital settings, growing PN solution demand due to an increase in geriatric population & patients suffering from chronic diseases requiring long-term care.
Regional Analysis:
North America dominated the global thalomid market in 2017. The presence of a large number of key players coupled with high healthcare expenditure and favorable reimbursement policies are some factors attributing to its largest share. In addition, increasing demand for generic drugs due to patent expirations is expected to further fuel the regional market growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income, improving healthcare infrastructure and growing target population base especially in China & India. Furthermore, economic development coupled with government initiatives such as Make in India implemented by Indian government is expected drive industrial production which will subsequently drive product demand over next seven years.
Growth Factors:
- Increasing incidence of multiple myeloma: The global incidence of multiple myeloma is increasing at a significant rate. This is expected to drive the demand for Thalomid in the coming years.
- Rising awareness about Thalomid: There is a growing awareness among physicians and patients about the benefits of Thalomid therapy for treating multiple myeloma. This is likely to boost the demand for this drug in the coming years.
- Availability of generic versions: A number of generic versions of thalidomide are available in several countries, which has helped to make this drug more affordable and accessible to patients worldwide. This is likely to fuel market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Thalomid Market Research Report
By Type
50mg, 100mg, 200mg
By Application
Retail Pharmacy, Hospital Pharmacy, Other
By Companies
Celgene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Thalomid Market Report Segments:
The global Thalomid market is segmented on the basis of:
Types
50mg, 100mg, 200mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Retail Pharmacy, Hospital Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
Highlights of The Thalomid Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 50mg
- 100mg
- 200mg
- By Application:
- Retail Pharmacy
- Hospital Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Thalomid Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Thalomid is a medication used to treat various types of cancer. It works by stopping the growth of cancer cells.
Some of the key players operating in the thalomid market are Celgene.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Thalomid Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Thalomid Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Thalomid Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Thalomid Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Thalomid Market Size & Forecast, 2020-2028
4.5.1 Thalomid Market Size and Y-o-Y Growth
4.5.2 Thalomid Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 50mg
5.2.2 100mg
5.2.3 200mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Retail Pharmacy
6.2.2 Hospital Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Thalomid Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Thalomid Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 50mg
9.6.2 100mg
9.6.3 200mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Retail Pharmacy
9.10.2 Hospital Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 50mg
10.6.2 100mg
10.6.3 200mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Retail Pharmacy
10.10.2 Hospital Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 50mg
11.6.2 100mg
11.6.3 200mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Retail Pharmacy
11.10.2 Hospital Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 50mg
12.6.2 100mg
12.6.3 200mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Retail Pharmacy
12.10.2 Hospital Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 50mg
13.6.2 100mg
13.6.3 200mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Retail Pharmacy
13.10.2 Hospital Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Thalomid Market: Competitive Dashboard
14.2 Global Thalomid Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
